4172.TWO InnoPharmax Inc.

Healthcare Drug Manufacturers - Specialty & Generic Taiwan OTC Exchange
9.04 TWD
Close of Nov 6, 2026
8.64 23.25
Market cap
TWD 1.08B
P/E
-
P/B
2.14x
ROE
-44.0%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the fiscal year ending Dec 2025.

Is 4172.TWO undervalued?

Graham number

The Graham number of InnoPharmax Inc. cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

InnoPharmax Inc. fundamental analysis

No fundamental analysis for InnoPharmax Inc. yet.

InnoPharmax Inc. stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About InnoPharmax Inc.

InnoPharmax Inc., a specialty pharmaceutical company, develops and commercializes products for the treatment of oncology and other specialties in Taiwan. The company offers Imipenem and Cilastatin sodium solution under the Bestnem brand for the treatment of infections caused by susceptible organisms, such as lower respiratory tract, skin and skin structure, intra-abdominal, gynecologic, bone, and joint infections; contrast agents, such as gadopentetate dimeglumine under the …

Full company profile